Currently, there are 298.36M common shares owned by the public and among those 223.95M shares have been available to trade.
The company’s stock has a 5-day price change of 5.21% and 104.83% over the past three months. ABCL shares are trading 51.43% year to date (YTD), with the 12-month market performance up to 44.71% higher. It has a 12-month low price of $1.89 and touched a high of $4.33 over the same period. ABCL has an average intraday trading volume of 5.53 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.17%, 50.57%, and 53.33% respectively.
Institutional ownership of AbCellera Biologics Inc (NASDAQ: ABCL) shares accounts for 41.08% of the company’s 298.36M shares outstanding.
It has a market capitalization of $1.27B and a beta (3y monthly) value of 0.62. The earnings-per-share (ttm) stands at -$0.57. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.67% over the week and 8.75% over the month.
Earnings per share for the fiscal year are expected to decrease by -11.29%, and 18.84% over the next financial year. EPS should grow at an annualized rate of 0.83% over the next five years, compared to -107.74% over the past 5-year period.
Looking at the support for the ABCL, a number of firms have released research notes about the stock. Leerink Partners stated their Outperform rating for the stock in a research note on July 07, 2025, with the firm’s price target at $5. The Benchmark Company was of a view on February 22, 2024 that the stock is Buy, while KeyBanc Capital Markets gave the stock Overweight rating on December 05, 2023, issuing a price target of $6. The Benchmark Company on their part issued Hold rating on November 06, 2023.
